Alnylam Pharmaceuticals Flying High Despite Limited Near-Term Clinical Catalysts

 

The market has proved much more interested in Alynylam Pharmaceuticals (NASDAQ:ALNY) since my last update, with the shares up 45% and far head of the two major biotech indices, as the market has shrugged off some strong competitor data and looked past a period of relatively little thesis-changing clinical data.

While I’m bullish on the company’s pipeline, including vutrisiran for ATTR amyloidosis and zilebesiran for hypertension, I can’t argue that the shares are going underappreciated now. There are still potential incremental value-drivers (like cemdisiran) and early-stage programs well worth watching in areas like gout and NASH, but the current valuation seems to capture that pretty well.

 

Click the link for the full article: 

Alnylam Pharmaceuticals Flying High Despite Limited Near-Term Clinical Catalysts